Medical writting

Asking for Preferences

It looks like your message got cut off. Could you clarify what you meant by "S"?

For your clinical case report, I need a few details to get started:

What is the condition/diagnosis? (e.g., a rare disease, unusual presentation, unexpected outcome)
Patient details - age, sex, presenting complaint, history, key investigations, treatment, and outcome
Do you have real case data, or should I draft a template/fictional case for a specific condition?

Please share whatever you have and I'll write the full case report.

Psoriasis

Asking for Preferences

Reading File

Searching PubMed

plaque psoriasis clinical management

Finding Sources

Reading File

Finding Sources

I now have excellent reference material from Fitzpatrick's Dermatology and the Textbook of Family Medicine. Let me compile the full clinical case report.

Clinical Case Report: Plaque Psoriasis

A Fictional Illustrative Case for Educational Purposes

Title

Chronic Plaque Psoriasis Presenting with Widespread Erythematous Scaly Plaques: A Case Report and Review of Management

Abstract

Plaque psoriasis is the most common form of psoriasis, accounting for 80-90% of all cases. It is a chronic, immune-mediated inflammatory skin disorder characterized by thickened erythematous plaques covered with silvery-white scale. We report the case of a 34-year-old male presenting with a 3-year history of progressive erythematous scaly plaques over the elbows, knees, and lower back. Diagnosis was established clinically and confirmed on skin biopsy. The patient was managed successfully with a combination of high-potency topical corticosteroids and calcipotriene with marked improvement at 8 weeks. This case highlights the clinical features, pathophysiology, differential diagnosis, and stepwise management of chronic plaque psoriasis.

Keywords: Psoriasis, plaque psoriasis, topical corticosteroids, calcipotriene, biologic therapy, skin biopsy

1. Introduction

Psoriasis affects approximately 1-2% of the U.S. population and imposes a significant burden on quality of life. It is a chronic, relapsing, immune-mediated disorder driven by Th1 and Th17-polarized T-cell responses leading to keratinocyte hyperproliferation and epidermal hyperplasia (acanthosis). The disease has two peak age ranges of onset: 16 to 22 years and 57 to 60 years, with a strong genetic predisposition - when both parents are affected, the risk to offspring may be as high as 50%; with one parent affected, the risk is approximately 16%.

Plaque psoriasis (psoriasis vulgaris) is the dominant subtype and presents as well-demarcated, erythematous plaques covered with silvery-white scale, most commonly affecting the elbows, knees, scalp, and lumbosacral region. Despite being a well-recognized condition, delays in diagnosis and suboptimal management are common. This case report aims to illustrate a typical presentation and evidence-based management approach.

(Fitzpatrick's Dermatology, Vol. 1 & 2; Textbook of Family Medicine, 9e)

2. Case Presentation

2.1 Patient Information

Age/Sex: 34-year-old male
Occupation: Office administrator
Ethnicity: South Asian
Chief Complaint: Itchy, scaly skin lesions over elbows, knees, and lower back for 3 years

2.2 History of Present Illness

The patient presented to the dermatology outpatient clinic with a 3-year history of gradually worsening, well-defined erythematous plaques with overlying thick silvery-white scale. Lesions first appeared on both elbows and progressively involved the knees, lower back, and scalp margin. He reported moderate pruritus (Visual Analog Scale 5/10) and significant social embarrassment. Symptoms were worse during winter and improved modestly with sun exposure. He denied any joint pains, nail changes, or eye symptoms.

Triggers identified:

Psychological stress (workplace)
Prior use of oral prednisolone for an unrelated condition (prescribed by a general practitioner 6 months ago), after cessation of which lesions acutely worsened

2.3 Past Medical History

No known chronic illnesses
No prior hospitalization
No history of streptococcal throat infection

2.4 Family History

Father diagnosed with psoriasis

2.5 Medication History

Topical over-the-counter moisturizers (partial relief)
Brief course of oral prednisolone (5 mg/day for 2 weeks) - discontinued 6 months ago; followed by flare

2.6 Social History

Non-smoker; occasional alcohol consumption
Moderate psychological stress at work

2.7 Review of Systems

No fever, joint swelling, or ocular redness
No recent sore throat or upper respiratory tract infection

3. Physical Examination

General: Well-built male, no acute distress. Afebrile.

Skin Examination:

Multiple well-demarcated erythematous plaques of varying sizes (2-10 cm), covered with thick, adherent, silvery-white scale
Distribution: bilateral elbows (extensor surfaces), bilateral knees (extensor surfaces), lumbosacral region
Auspitz sign: Positive (pinpoint bleeding upon removal of scale)
Koebner phenomenon: Present (new lesion along a scratch line on the forearm)
Scalp: scaling plaques along the posterior hairline
Nails: two fingernails showing pitting; no onycholysis

Joints: No synovitis, no enthesitis, full range of motion in all joints.

Lymph Nodes: Not palpable.

Body Surface Area (BSA) affected: Approximately 12% (moderate disease)

PASI Score: 14.2 (Psoriasis Area and Severity Index - moderate disease)

4. Investigations

Investigation	Result
Complete Blood Count (CBC)	Within normal limits
Liver Function Tests (LFT)	Normal
Renal Function Tests (RFT)	Normal
Fasting Blood Glucose	Normal
Lipid Profile	Normal
Anti-streptolysin O (ASO) titre	Negative
HIV screening	Negative
KOH preparation (from lesion scraping)	No fungal hyphae seen
Skin Biopsy (punch biopsy, elbow lesion)	Parakeratosis, acanthosis, elongated rete ridges, Munro microabscesses (neutrophils in stratum corneum), dilated tortuous dermal capillaries - consistent with psoriasis

5. Diagnosis

Chronic plaque psoriasis (psoriasis vulgaris) - moderate severity (PASI 14.2, BSA 12%)

5.1 Differential Diagnosis Considered

Condition	Distinguishing Feature
Seborrhoeic dermatitis	Greasy scale in seborrheic areas; no Auspitz sign
Tinea corporis	Annular border, KOH positive for hyphae
Eczema/Atopic dermatitis	Flexural distribution, lichenification; no silvery scale
Secondary syphilis	Generalized rash including palms/soles, positive serology
Pityriasis rosea	Herald patch, self-limiting course
Lichen planus	Violaceous flat-topped papules with Wickham striae

6. Management

Management was guided by disease severity (moderate, BSA 12%, PASI 14.2) and was escalated in a stepwise manner.

6.1 Patient Education

Nature of psoriasis explained as a chronic relapsing disease - not contagious
Avoidance of triggers: stress management, avoidance of skin trauma, smoking cessation counseling
Counseled explicitly against oral or systemic corticosteroids - systemic steroids are contraindicated as they can precipitate life-threatening generalized pustular psoriasis upon withdrawal

6.2 Topical Therapy (First-line)

Clobetasol propionate 0.05% ointment (ultra-high potency corticosteroid) applied once daily to plaques on trunk and extremities for 4 weeks, then tapered. Meta-analysis data shows 68-89% of patients achieve clear or near-clear improvement with clobetasol.
Calcipotriene (vitamin D analog) ointment 0.005% applied once daily to same plaques on alternate days with clobetasol (combination approach). Combination topical steroids + calcipotriene provides increased efficacy with fewer side effects compared to either agent alone.
Scalp: Clobetasol propionate 0.05% solution applied to scalp plaques nightly.
Emollients/Moisturizers: Applied liberally twice daily to all affected areas to reduce scaling and pruritus.

6.3 Systemic Therapy (Consideration for Non-responders)

Given this patient's moderate disease, the following systemic options were discussed as second-line escalation if topical therapy failed at 8 weeks:

Methotrexate 7.5-15 mg weekly oral dose - effective for widespread disease not responding to topical therapy; requires baseline LFT, CBC, hepatitis screening
Acitretin (systemic retinoid) - for widespread or palmar-plantar psoriasis resistant to topical treatment
Narrowband UVB (NB-UVB) phototherapy - highly effective; can accelerate clearance in fewer sessions

6.4 Biologic Therapy (for Moderate-Severe/Refractory Disease)

If the patient progresses or fails systemic therapy, biologic agents were explained:

Etanercept (anti-TNF, subcutaneous) - especially valuable in psoriatic arthritis
Adalimumab (anti-TNF, subcutaneous) - effective for moderate-severe psoriasis
Ustekinumab (anti-IL-12/23, subcutaneous) - significantly reduces signs and symptoms

(Textbook of Family Medicine 9e, p. 929-930; Fitzpatrick's Dermatology)

7. Follow-up and Outcome

At 4 weeks: Significant reduction in scaling and erythema. PASI reduced from 14.2 to 8.5. Patient reported improved quality of life. No adverse effects from topical therapy.

At 8 weeks: Near-complete clearance of elbow and knee plaques. PASI 3.1 (mild). Scalp improved by approximately 80%. Patient maintained on twice-weekly clobetasol and daily calcipotriene as maintenance therapy.

At 6 months: Patient in remission on maintenance calcipotriene monotherapy with intermittent emollients. No systemic therapy required.

8. Discussion

This case illustrates the typical clinical features, diagnostic approach, and stepwise management of chronic plaque psoriasis. Several teaching points are highlighted:

1. Pathophysiology: Psoriasis results from hyperplasia of the epidermis driven by Th1/Th17-polarized T-cell inflammation, with neutrophils, macrophages, and dendritic cells contributing to the characteristic histological features including Munro microabscesses and elongated rete ridges.

2. Clinical Clues: The combination of a positive Auspitz sign (pinpoint bleeding on scale removal) and Koebner phenomenon (new lesions at trauma sites) are highly characteristic and aid clinical diagnosis. The extensor distribution of plaques and family history further supported the diagnosis.

3. Steroid Pitfall: A critical point in this case is that a previous clinician had prescribed oral prednisolone, which temporarily suppressed the disease but triggered a significant flare on withdrawal. This reflects a key contraindication - systemic corticosteroids should not be used in psoriasis as they risk precipitating life-threatening pustular psoriasis.

4. Combination Topical Therapy: The combination of high-potency topical steroids with calcipotriene or tazarotene represents the most effective topical strategy, with improved outcomes and a more favorable side-effect profile compared to monotherapy.

5. Severity-Based Escalation: Using validated tools such as the PASI score and BSA assessment allows standardized, evidence-based escalation from topical to systemic or biologic therapy.

9. Conclusion

Chronic plaque psoriasis is a common and impactful dermatological condition requiring accurate diagnosis and individualized, severity-based management. This case demonstrates that moderate psoriasis can be effectively managed with topical combination therapy (corticosteroids + calcipotriene) when initiated appropriately. Clinicians must counsel patients against systemic corticosteroids. Patients failing topical therapy should be escalated to methotrexate, phototherapy, or biologic agents. Long-term follow-up remains essential given the chronic relapsing nature of the disease.

References

Fitzpatrick's Dermatology in General Medicine, 9th Edition. McGraw-Hill.
Textbook of Family Medicine, 9th Edition (Rakel). Elsevier.
Afifi T, et al. Topical therapies for psoriasis: evidence-based review. Am J Clin Dermatol. 2005.
Nast A, et al. Topical corticosteroid therapy for psoriasis. J Dtsch Dermatol Ges. 2007.
Gottlieb AB, et al. Ustekinumab for psoriatic arthritis. N Engl J Med. 2009.
Choon SE, et al. Asia-Pacific consensus on management of generalized pustular psoriasis. J Dermatol. 2024 Dec. (PMID: 39390737)

Note: This is a fictional illustrative case created for educational and medical writing purposes. Patient details are entirely fictitious. Dosages and treatment protocols should be verified against current local guidelines before clinical application.

Create an infographic showing the stepwise psoriasis treatment algorithm

Generating Image

A clean, professional medical infographic titled "Psoriasis Treatment Algorithm" showing a stepwise vertical flowchart with 4 steps/levels: STEP 1 - MILD DISEASE (BSA less than 10%, PASI less than 10): Blue box at top. Contents: Topical Corticosteroids (e.g. Clobetasol 0.05%), Vitamin D Analogues (Calcipotriene), Combination Topical Therapy, Emollients & Moisturizers, Salicylic Acid (keratolytic). Arrow pointing down labeled "Inadequate Response at 8-12 weeks" STEP 2 - MODERATE DISEASE (BSA 10-30%, PASI 10-20): Green box. Contents: Narrowband UVB Phototherapy (NB-UVB), PUVA Phototherapy, Continue optimized topical therapy. Arrow pointing down labeled "Inadequate Response" STEP 3 - MODERATE-SEVERE DISEASE: Orange box. Contents: Methotrexate (7.5-25mg/week oral), Cyclosporine (short-term), Acitretin (systemic retinoid), Apremilast (PDE4 inhibitor). Arrow pointing down labeled "Inadequate Response or Contraindications" STEP 4 - SEVERE / REFRACTORY DISEASE: Red box. Contents: Biologic Therapy - Anti-TNF: Adalimumab, Etanercept, Infliximab; Anti-IL-17: Secukinumab, Ixekizumab; Anti-IL-23: Ustekinumab, Risankizumab Side panel with red warning box: "AVOID systemic corticosteroids - risk of rebound pustular psoriasis" Bottom section: Assessment Tools: PASI Score, BSA%, DLQI (Quality of Life). Color coded severity bar on the left side from green (mild) to red (severe). Clean white background, modern medical style, icons for pills, injection syringes, UV light. Title at top in dark navy blue bold text.

Here is your Psoriasis Treatment Algorithm infographic. It covers:

Step 1 (Mild) - Topical agents: corticosteroids, calcipotriene, combination therapy
Step 2 (Moderate) - Phototherapy: NB-UVB and PUVA
Step 3 (Moderate-Severe) - Systemic agents: methotrexate, cyclosporine, acitretin, apremilast
Step 4 (Severe/Refractory) - Biologic therapy: anti-TNF, anti-IL-17, anti-IL-23 agents
Warning panel - Avoid systemic corticosteroids (risk of rebound pustular psoriasis)
Assessment tools - PASI, BSA%, and DLQI at the bottom

Let me know if you'd like any changes - different colors, added content, a different layout, or a downloadable file version (e.g. as part of a PPTX or PDF).

This is a shared conversation. Sign in to Orris to start your own chat.